Angiopoietins, abdominal aortic aneurysm and atherosclerosis

Atherosclerosis

Volumn 214, Issue 2, 2011, Pages 237-243

  Trollope, Alexandra F ^a   Golledge, Jonathan ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Abdominal aortic aneurysm; Angiopoietins; Atherosclerosis

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; VASCULOTROPIN;

ABDOMINAL AORTA ANEURYSM; ANGIOGENESIS; ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS;

ANGIOPOIETINS; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; ATHEROSCLEROSIS; DISEASE PROGRESSION; HUMANS; INFLAMMATION MEDIATORS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 79151483351     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.08.051     Document Type: Review

References (85)

1. Golledge J., Norman P. Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors?. Arterioscler Thromb Vasc Biol 2010, 30:1075-1077.
2. Golledge J., Muller J., Daugherty A., Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006, 26:2605-2613.
3. Solberg L.A., Strong J.P. Risk factors and atherosclerotic lesions. A review of autopsy studies. Atherosclerosis 1983, 3:187-198.
4. Silverstein R.L., Nachman R.L. Angiogenesis and atherosclerosis. Circulation 1999, 100:783-785.
5. Kahlon R., Shapero J., Gotlieb A.I. Angiogenesis in atherosclerosis. Can J Cardiol 1992, 8:60-64.
6. Thompson M.M., Jones L., Nasim A., Sayers R.D., Bell P.R.F. Angiogenesis in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1996, 11:464-469.
7. Choke E., Cockerill G., Dawson J., et al. The role of angiogenesis in abdominal aortic aneurysm rupture. Atherosclerosis 2008, 199:463-464.
8. Mustonen T., Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995, 129:895-898.
9. Suri C., Jones P.F., Patan S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-1180.
10. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 9:353-364.
11. Davis S., Aldrich T.H., Jones P.F., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87:1161-1169.
12. Sundberg C., Kowanetz M., Brown L.F., Detmar M., Dvorak H.F. Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest 2002, 84:387-401.
13. Dallabrida S.M., Ismail N.S., Pravda E.A., et al. Integrin binding angiopoietin-1 monomers reduce cardiac hypertrophy. FASEB J 2008, 22:3010-3023.
14. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
15. Hildbrand P., Cirulli V., Prinsen R.C., et al. The role of angiopoietins in the development of endothelial cells from cord blood CD34+ progenitors. Blood 2004, 104:2010-2019.
16. Holash J., Wiegand S.J., Yancopoulos G.D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999, 18:5356-5362.
17. Lobov I.B., Brooks P.C., Lang R.A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002, 99:11205-11210.
18. Valenzuela D.M., Griffiths J.A., Rojas J., et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 1999, 96:1904-1909.
19. Teichert-Kuliszewska K., Maisonpierre P.C., Jones N., et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 2001, 49:659-670.
20. Davis S., Papadopoulos N., Aldrich T.H., et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 2003, 10:38-44.
21. Dumont D.J., Gradwohl G., Fong G.H., et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994, 16:1897-1909.
22. Sato T.N., Tozawa Y., Deutsch U., et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995, 376:40-74.
23. Gale N.W., Thurston G., Hackett S.F., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002, 3:411-423.
24. De Palma M., Venneri M.A., Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 2003, 14:1193-1206.
25. De Palma M., Venneri M.A., Galli R., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 3:211-226.
26. Singh H., Milner C.S., Aguilar Hernandez M.M., Patel N., Brindle N.P. Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases. Cell Signal 2009, 21:1346-1350.
27. Chan B., Yuan H.T., Ananth Karumanchi S., Sukhatme V.P. Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules. Biochem Biophys Res Commun 2008, 371:475-479.
28. DeBusk L.M., Hallahan D.E., Lin P.C. Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res 2004, 298:167-177.
29. Saharinen P., Kerkelä K., Ekman N., et al. Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J Cell Biol 2005, 169:239-243.
30. Tsiamis A.C., Morris P.N., Marron M.B., Brindle N.P. Vascular endothelial growth factor modulates the Tie-2:Tie-1 receptor complex. Microvasc Res 2002, 63:149-158.
31. Hansen T.M., Singh H., Tahir T.A., Brindle N.P. Effects of angiopoietins-1 and -2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface. Cell Signal 2010, 22:527-532.
32. Seegar T.C, Eller B., Tzvetkova-Robev D., et al. Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 2010, 37:643-655.
33. Reusch P., Barleon B., Weindel K., et al. Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood. Angiogenesis 2001, 4:123-131.
34. Yabkowitz R., Meyer S., Black T., et al. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood 1999, 93:1969-1979.
35. Findley C.M., Mitchell R.G., Duscha B.D., Annex B.H., Kontos C.D. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol 2008, 52:387-393.
36. Suri C., McClain J., Thurston G., et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998, 282:468-471.
37. Calvi C., Dentelli P., Pagano M., et al. Angiopoietin 2 induces cell cycle arrest in endothelial cells: a possible mechanism involved in advanced plaque neovascularization. Arterioscler Thromb Vasc Biol 2004, 24:511-518.
38. Korpelainen E.I., Kärkkäinen M., Gunji Y., Vikkula M., Alitalo K. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 1999, 18:1-8.
39. Chen Z., Han Z.C. STAT3: a critical transcription activator in angiogenesis. Med Res Rev 2008, 28:185-200.
40. Brophy C.M., Reilly J.M., Smith G.J., Tilson M.D. The role of inflammation in nonspecific abdominal aortic aneurysm disease. Ann Vasc Surg 1991, 5:229-233.
41. Rijbroek A., Moll F.L., Dijk H.A., Meijer R. Inflammation of the abdominal aortic aneurysm wall. Eur J Vasc Surg 1994, 8:41-46.
42. Rehm J.P., Grange J.J., Baxter B.T. The formation of aneurysm. Sem Vasc Surg 1998, 11:193-202.
43. Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev 2007, 65:S140-S146.
44. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
45. Golledge J., Norman P.E. Pathophysiology of abdominal aortic aneurysm relevant to improvements in patients' management. Curr Opin in Cardiol 2009, 24:532-538.
46. Shimizu K., Mitchell R.N., Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006, 26:987-994.
47. Weintraub N.L. Understanding abdominal aortic aneurysm. N Eng J Med 2009, 361:1114-1116.
48. Hughes D.P., Marron M.B., Brindle N.P. The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2. Circ Res 2003, 92:630-636.
49. Thurston G. Role of angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003, 314:61-68.
50. Gamble J.R., Drew J., Trezise L., et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 2000, 87:603-607.
51. Kim I., Moon S.O., Park S.K., Chae S.W., Koh G.Y. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 2001, 89:477-479.
52. Mangan S.H., Van Campenhout A., Rush C., Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res 2007, 76:494-505.
53. Reed J.C. The survivin saga goes in vivo. J Clin Invest 2001, 108:965-969.
54. Fiedler U., Reiss Y., Scharpfenecker M., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006, 12:235-239.
55. Murdoch C., Tazzyman S., Webster S., Lewis C.E. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007, 178:7405-7411.
56. Neagoe P.E., Brkovic A., Hajjar F., Sirois M.G. Expression and release of angiopoietin-1 from human neutrophils: intracellular mechanisms. Growth Factors 2009, 27:335-344.
57. Nishishita T., Lin P.C. Angiopoietin 1, PDGF-B, and TGF-beta gene regulation in endothelial cell and smooth muscle cell interaction. J Cell Biochem 2004, 91:584-593.
58. Li J.J., Huang Y.Q., Basch R., Karpatkin S. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 2001, 85:204-206.
59. Lemieux C., Maliba R., Favier J., et al. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood 2005, 15:1523-1530.
60. Ahmed A., Fujisawa T., Niu X.L., et al. Angiopoietin-2 confers atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide. Circ Res 2009, 104:1333-1336.
61. Chun H.J., Ali Z.A., Kojima Y., et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008, 118:3343-3354.
62. Leeper N.J., Tedesco M.M., Kojima Y., et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol 2009, 296:H1329-H1335.
63. Kidoya H., Ueno M., Yamada Y., et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 2008, 27:522-534.
64. Chen M.M., Ashley E.A., Deng D.X., et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003, 23:1432-1439.
65. Nykänen A.I., Krebs R., Saaristo A., et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 2003, 107:1237-1239.
66. Hauer A.D., Habets K.L., van Wanrooij E.J., et al. Vaccination against TIE2 reduces atherosclerosis. Atherosclerosis 2009, 204:365-367.
67. Fernández-Hernando C., Ackah E., Yu J., et al. Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab 2007, 6:446-457.
68. Duda D.G., Fukumura D., Jain R.K. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 2004, 10:143-145.
69. Post S., Peeters W., Busser E., et al. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res 2008, 45:244-250.
70. Chong A.Y., Caine G.J., Freestone B., Blann A.D., Lip G.Y. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol 2004, 43:423-428.
71. Freestone B., Chong A.Y., Lim H.S., Blann A., Lip G.Y. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?. Ann Med 2005, 37:365-372.
72. Kümpers P., Lukasz A., David S., et al. Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care 2008, 12:R147.
73. Helfrich I., Edler L., Sucker A., et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009, 15:1384-1392.
74. Patel J.V., Hoong S.L., Varughese G., Hughes E., Lip G.Y.H. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med 2008, 40:215-222.
75. Virmani R., Kolodgie F.D., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Aterioscler Thromb Vasc Biol 2005, 25:2054-2061.
76. Roviezzo F., Tsigkos S., Kotanidou A., et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 2005, 314:738-744.
77. Abdel-Malak N.A., Mofarrahi M., Mayaki D., Khachigian L.M., Hussain S.N. Early growth response-1 regulates angiopoietin-1-induced endothelial cell proliferation, migration, and differentiation. Arterioscler Thromb Vasc Biol 2009, 29:209-216.
78. Papapetropoulos A., Fulton D., Mahboubi K., et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000, 275:9102-9105.
79. Kim I., Kim J.H., Moon S.O., et al. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 2000, 19:4549-4552.
80. Harfouche R., Hussain S.N.A. Signaling and regulation of endothelial cell survival by angiopoietin-2. Am J Physiol Heart Circ Physiol 2006, 291:H1635-H1645.
81. Choke E., Cockerill G.W., Dawson J., et al. Increased angiogenesis at the site of abdominal aortic aneurysm rupture. Ann N Y Acad Sci 2006, 1085:315-319.
82. Sturn D.H., Feistritzer C., Mosheimer B.A., et al. Angiopoietin affects neutrophil migration. Microcirculation 2005, 12:393-403.
83. Feistritzer C., Mosheimer B.A., Sturn D.H., et al. Expression and function of the angiopoietin receptor Tie-2 in human eosinophils. J Allergy Clin Immunol 2004, 114:1077-1084.
84. Lim H.S., Blann A.D., Chong A.Y., Freestone B., Lip G.Y. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004, 27:1924-2918.
85. David S., Kümpers P., Lukasz A., et al. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. J Hypertens 2009, 27:1641-1647.